Daniel Tarade
Overview
Explore the profile of Daniel Tarade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stuart S, Tarade D, Ohh M
Sci Rep
. 2024 Jun;
14(1):14799.
PMID: 38926538
The oxygen-labile transcription factor called hypoxia-inducible factor (HIF) is responsible for the cellular and organismal adaptive response to reduced oxygen availability. Deregulation of HIF is associated with the pathogenesis of...
2.
Ferens F, Taber C, Stuart S, Hubert M, Tarade D, Lee J, et al.
Commun Biol
. 2024 Feb;
7(1):240.
PMID: 38418569
Pacak-Zhuang syndrome is caused by mutations in the EPAS1 gene, which encodes for one of the three hypoxia-inducible factor alpha (HIFα) paralogs HIF2α and is associated with defined but varied...
3.
Ohh M, Taber C, Ferens F, Tarade D
Elife
. 2022 Aug;
11.
PMID: 36040300
von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that causes a predisposition to renal clear-cell carcinoma, hemangioblastoma, pheochromocytoma, and autosomal-recessive familial polycythemia. pVHL is the substrate conferring subunit...
4.
Tarade D, He S, St-Germain J, Petroff A, Murphy A, Raught B, et al.
Protein Sci
. 2020 Jun;
29(8):1843-1850.
PMID: 32535973
von Hippel-Lindau protein (pVHL) is the tumor suppressor responsible for ubiquitylating the hypoxia-inducible factor (HIF) family of transcription factors for degradation under normoxic conditions. There are two major pVHL isoforms...
5.
Tarade D, Lee J, Ohh M
Nat Commun
. 2019 Jul;
10(1):3293.
PMID: 31337753
Duplication of ancestral hypoxia-inducible factor (HIF)α coincided with the evolution of vertebrate species. Paralogs HIF1α and HIF2α are the most well-known factors for modulating the cellular transcriptional profile following hypoxia....
6.
Tarade D, Robinson C, Lee J, Ohh M
Nat Commun
. 2018 Aug;
9(1):3359.
PMID: 30135421
It is definitively established that mutations in transcription factor HIF-2α are causative of both neuroendocrine tumors (class 1 disease) and polycythemia (class 2 disease). However, the molecular mechanism that underlies...
7.
Ma D, Pignanelli C, Tarade D, Gilbert T, Noel M, Mansour F, et al.
Sci Rep
. 2018 Jul;
8:46998.
PMID: 29972149
This corrects the article DOI: 10.1038/srep42957.
8.
Ma D, Gilbert T, Pignanelli C, Tarade D, Noel M, Mansour F, et al.
FASEB J
. 2017 Sep;
32(1):417-430.
PMID: 28928246
Harsh adverse effects as a result of nonspecific targeting of chemotherapeutics currently pose obstacles in cancer therapy; thus, it would be invaluable to devise novel approaches to specifically target cancer...
9.
Tarade D, Ma D, Pignanelli C, Mansour F, Simard D, van den Berg S, et al.
PLoS One
. 2017 Mar;
12(3):e0171806.
PMID: 28253265
The cis-stilbene, combretastatin A4 (CA4), is a potent microtubule targeting and vascular damaging agent. Despite promising results at the pre-clinical level and extensive clinical evaluation, CA4 has yet to be...
10.
Ma D, Pignanelli C, Tarade D, Gilbert T, Noel M, Mansour F, et al.
Sci Rep
. 2017 Feb;
7:42957.
PMID: 28220885
Enhanced mitochondrial stability and decreased dependence on oxidative phosphorylation confer an acquired resistance to apoptosis in cancer cells, but may present opportunities for therapeutic intervention. The compound pancratistatin (PST) has...